Agios Opens Doors To Other Investors, Expands Into Genetic Disorders
This article was originally published in The Pink Sheet Daily
Executive Summary
Agios brings in a $78 million in financing from both previous venture investors and new public investor funds, as it embarks on research of rare diseases caused by an inborn error of metabolism.
Register for our free email digests: